--- title: "Aier Eye Hospital goes public in Hong Kong: A decade of going abroad, now setting sail again" type: "News" locale: "en" url: "https://longbridge.com/en/news/287832195.md" description: "Aier Eye Hospital submitted its H-share listing prospectus to the Hong Kong Stock Exchange on May 27, with Chairman Chen Bang stating that this move is an important step in the company's globalization strategy. The prospectus shows that the global ophthalmology medical market is growing rapidly, with an expected market size of USD 30.45 billion by 2035. Aier's market share in China has increased from 6.1% in 2015 to 11.7% in 2025, and it holds a leading position in global ophthalmic services" datetime: "2026-05-27T23:42:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287832195.md) - [en](https://longbridge.com/en/news/287832195.md) - [zh-HK](https://longbridge.com/zh-HK/news/287832195.md) generator: "portal-rs" --- # Aier Eye Hospital goes public in Hong Kong: A decade of going abroad, now setting sail again On the evening of May 27, Aier Eye Hospital officially submitted its H-share listing prospectus to the Hong Kong Stock Exchange. At the 2025 annual shareholders' meeting, Chairman Chen Bang clearly stated: "The listing on the Hong Kong Stock Exchange is based on the company's long-term strategic considerations, an important step in achieving globalization, and an inevitable step. The proportion of overseas business is continuously increasing, and its contribution is growing. After ten years of going abroad, we have accumulated rich experience overseas, and most of our existing hospitals have been operating for six to seven years, now we have reached a stage for further development." So, what other details does Aier's Hong Kong stock prospectus disclose? Why is this step considered an inevitable move for Aier Eye Hospital to promote its globalization layout? **1\. Confidence from the Industry** As an industry "model student," Aier Eye Hospital's prospectus is the best report on the status of the ophthalmic medical industry. Industry data shows that both the global and Chinese ophthalmic medical service markets are in a rapid growth phase with continuously increasing penetration rates and expanding service scenarios. From 2020 to 2025, the global ophthalmic medical service market is expected to have a compound annual growth rate of approximately 4.8%, with the market size projected to reach about USD 30.45 billion by 2035. Driven by multiple factors such as accelerated population aging, technological innovation, and the expansion of the ophthalmic talent pool, the Chinese ophthalmic medical market is developing rapidly. Along with the industry's growth, Aier's market share in China's ophthalmic medical service market is steadily increasing from 6.1% in 2015 to 11.7% in 2025. Aier's prospectus details many advantages of the company, such as the supply of high-quality ophthalmic medical services, a vast accumulation of clinical cases, a standardized operational system formed through long-term market practice, and the trust and brand reputation built through continuous quality service. Notably, Aier has not only established an ophthalmic medical service network spanning Asia, Europe, and North America, but its treatment scale also continues to lead the industry. Since its listing on the A-share market in 2009, Aier has provided over 113 million outpatient ophthalmic medical services globally. According to industry consultant data, based on key dimensions such as the number of medical institutions, outpatient volume, surgical volume, and revenue by 2025, Aier ranks first among global ophthalmic medical service enterprises. In short, the ophthalmic market is optimistic in the long term, and Aier, as a leading "model," should be the most favored. **2\. Determination in Strategy** From the perspective of fundraising allocation, this listing in Hong Kong will primarily raise funds for three major directions: upgrading medical institutions in mainland China, mergers and acquisitions of domestic and foreign ophthalmic institutions, and the development of ophthalmic artificial intelligence and technology ecosystems, which closely align with Aier Eye Hospital's development strategy. According to the prospectus, the funds will be used to acquire overseas ophthalmic medical institutions with strong brand reputation and excellent clinical capabilities. Specifically, in mature markets such as Europe and North America, priority will be given to acquiring stable platform chain institutions to release endogenous growth potential; in high-growth markets such as Southeast Asia and South America, the focus will be on small and medium-sized institutions to further increase market share. The ultimate goal is to leverage Aier's mature international management capabilities to forge a high-quality integration path of "global development, local operation, and dual empowerment." The reporter learned that Clínica Baviera is the most convincing model. Since joining Aier Eye Hospital in 2017, the number of its institutions has increased from over 70 to 151 by the end of 2025, with revenue rising from approximately 100 million euros to 300 million euros, and a compound annual growth rate of net profit exceeding 20%. Data shows that by 2025, Aier's overseas business revenue will reach 3.057 billion yuan, a year-on-year increase of 16.47%, with the revenue share rising to 13.68%, and its contribution continuing to increase. Domestically, Aier Eye Hospital remains a solid development base. This fundraising is also focused on consolidating the domestic foundation, covering the construction and upgrading of the domestic network, in line with the company's "three-year tough battle" plan to tap internal potential and improve quality and efficiency. The prospectus shows that the funds raised will be used to acquire ophthalmic medical institutions both domestically and internationally, as well as to build and upgrade domestic medical institutions. The company stated that in the future, it will strengthen the ophthalmic outpatient network, weaving a multi-dimensional, multi-touchpoint service network. At the same time, for mature hospitals that have been operating for many years and have a good reputation, the company will promote upgrades and expansions, optimize the diagnosis and treatment environment, expand service capacity, enhance single-hospital operational efficiency and profitability, and improve the accessibility and penetration of high-quality medical services. **3\. "AI + Ophthalmology" Shows Vitality** In the wave of digitalization, technological empowerment has become a new trend in the development of the medical industry, containing infinite possibilities. Aier Eye Hospital's unique global largest ophthalmic chain network and comprehensive eye health application scenarios provide a rich soil for the development of the "AI + Ophthalmology" ecosystem. How to leverage "AI + Ophthalmology" to strengthen the company's core competitiveness has been an important topic for Aier Eye Hospital in recent years, and this fundraising will also be used for the development of ophthalmic artificial intelligence and technology ecosystems. The prospectus shows that Aier Eye Hospital currently has the largest full lifecycle digital health record system for eye health globally. By the end of 2025, it has integrated over 32 million high-quality individual clinical cases and 66 specialized disease datasets, including more than 300,000 cases of rare and difficult eye diseases, providing high-quality data support for AI model training, clinical validation, and technological innovation. In addition, the empowerment of AI technology systematically liberates medical supply capacity from three dimensions: quality, efficiency, and accessibility, breaking the boundaries of eye health service content and service targets, and promoting the breadth and depth of penetration of high-quality eye health services. Industry insiders point out that the Hong Kong stock market gathers global capital, with a high proportion of foreign professional investment institutions and a diverse funding structure; in terms of marketization, the Hong Kong stock market provides listed companies with greater autonomy in capital operations such as refinancing and equity incentives, facilitating enterprises to flexibly implement incentive measures and consolidate operational development momentum. Aier Eye Hospital's listing on the Hong Kong stock market will open up more flexible capital operation space for the company, allowing it to efficiently promote its globalization strategy through diversified financing methods in the future ### Related Stocks - [300015.CN](https://longbridge.com/en/quote/300015.CN.md) ## Related News & Research - [Canada's LSL Pharma Q2 revenue surges on acquisition boost, eye-drop launches](https://longbridge.com/en/news/296914529.md) - [18:00 ETMiles for Mercy raises more than $4,000 before riders hit the road](https://longbridge.com/en/news/296958797.md) - [13:50 ETGarageExperts Reaches 125 Territories at 2026 Midpoint, Fueled by Rising Demand](https://longbridge.com/en/news/296944816.md) - [China’s Sateri Carves Out Lyocell Business After Six-Year Build-Out](https://longbridge.com/en/news/297031735.md) - [Sand Grove Capital lifts Irish Continental stake to 4.49% from 3.58%](https://longbridge.com/en/news/296742335.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**